Literature DB >> 25590605

Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.

Jianjun Zhang1, Kathryn A Gold, Heather Y Lin, Stephen G Swisher, Yan Xing, J Jack Lee, Edward S Kim, William N William.   

Abstract

INTRODUCTION: Tumor size is a known prognostic factor for early stage non-small-cell lung cancer (NSCLC), but its significance in node-positive and locally invasive NSCLC has not been extensively characterized. We queried the Surveillance, Epidemiology, and End Results database to evaluate the prognostic value of tumor size for early stage and node-positive and locally invasive NSCLC.
METHODS: Patients in Surveillance, Epidemiology, and End Results registry with NSCLC diagnosed between 1998 and 2003 were analyzed. Tumor size was analyzed as a continuous variable. Other demographic variables included age, gender, race, histology, primary tumor extension, node status, and primary treatment modality (surgery vs. radiation). The Kaplan-Meier method was used to estimate overall survival (OS). Cox proportional hazard model was used to evaluate whether tumor size was an independent prognostic factor.
RESULTS: In all, 52,287 eligible patients were subgrouped based on tumor extension and node status. Tumor size had a significant effect on OS in all subgroups defined by tumor extension or node status. In addition, tumor size also had statistically significant effect on OS in 15 of 16 subgroups defined by tumor extension and nodal status after adjustment for other clinical variables. Our model incorporating tumor size had significantly better predictive accuracy than our alternative model without tumor size.
CONCLUSIONS: Tumor size is an independent prognostic factor, for early stage and node-positive and locally invasive disease. Prediction tools, such as nomograms, incorporating more detailed information not captured in detail by the routine tumor, node, metastasis classification, may improve prediction accuracy of OS in NSCLC.

Entities:  

Mesh:

Year:  2015        PMID: 25590605      PMCID: PMC4368494          DOI: 10.1097/JTO.0000000000000456

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  36 in total

1.  Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume.

Authors:  Kiyoshi Basaki; Yoshinao Abe; Masahiko Aoki; Hidehiro Kondo; Yoshiomi Hatayama; Shigeyuki Nakaji
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-13       Impact factor: 7.038

2.  Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.

Authors:  Makoto Sonobe; Masatsugu Nakagawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Kazuhiro Yanagihara; Yosuke Otake; Hiromi Wada; Fumihiro Tanaka
Journal:  J Surg Oncol       Date:  2007-01-01       Impact factor: 3.454

3.  Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size.

Authors:  Paul C Lee; Robert J Korst; Jeffrey L Port; Yaniv Kerem; Amanda L Kansler; Nasser K Altorki
Journal:  J Thorac Cardiovasc Surg       Date:  2006-10-30       Impact factor: 5.209

4.  The prognostic impact of tumor size in resected stage I non-small cell lung cancer: evidence for a two thresholds tumor diameters classification.

Authors:  Casali Christian; Storelli Erica; Uliano Morandi
Journal:  Lung Cancer       Date:  2006-09-22       Impact factor: 5.705

5.  Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy.

Authors:  Brian M Alexander; Megan Othus; Hale B Caglar; Aaron M Allen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-03       Impact factor: 7.038

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer.

Authors:  David Ball; Alan Mitchell; Dori Giroux; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

8.  Impact of size, histology, and gender on stage IA non-small cell lung cancer.

Authors:  Andrea Campione; Tommaso Ligabue; Luca Luzzi; Claudia Ghiribelli; Piero Paladini; Luca Voltolini; Maurizio Di Bisceglie; Mario Lonzi; Giuseppe Gotti
Journal:  Asian Cardiovasc Thorac Ann       Date:  2004-06

9.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

10.  Size of Stage IIIA primary lung cancers and survival: a surveillance, epidemiology and end results database analysis.

Authors:  Steven Maximus; Danh V Nguyen; Yi Mu; Royce F Calhoun; David T Cooke
Journal:  Am Surg       Date:  2012-11       Impact factor: 0.688

View more
  54 in total

1.  Robotic assisted VATS lobectomy for loco-regionally advanced non-small cell lung cancer.

Authors:  Simon R Turner; M Jawad Latif; Bernard J Park
Journal:  Video Assist Thorac Surg       Date:  2017-02-27

2.  Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types.

Authors:  Francesco Bianconi; Isabella Palumbo; Mario Luca Fravolini; Rita Chiari; Matteo Minestrini; Luca Brunese; Barbara Palumbo
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

3.  GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing Wnt/β-catenin signaling in lung adenocarcinoma.

Authors:  S Yuan; Z Yu; Q Liu; M Zhang; Y Xiang; N Wu; L Wu; Z Hu; B Xu; T Cai; X Ma; Y Zhang; C Liao; L Wang; P Yang; L Bai; Y Li
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

4.  Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer.

Authors:  O Abdel-Rahman
Journal:  Clin Transl Oncol       Date:  2017-05-11       Impact factor: 3.405

5.  Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients.

Authors:  Shoon Mya Aye; Lin Lin Kyi; Moe Hlaing; Aye Aye Myint; Khin Cho Win
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

6.  What is the effect of tumor diameter, lymph node metastases, and SUVmax value on prognosis in limited-stage small cell lung cancer?

Authors:  Filiz Çimen; Melike Aloglu; Sevim Düzgün; Ayşegül Şentürk; Şükran Atikcan; Özlem Özmen
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-09       Impact factor: 1.712

7.  Hybrid models for lung nodule malignancy prediction utilizing convolutional neural network ensembles and clinical data.

Authors:  Rahul Paul; Matthew B Schabath; Robert Gillies; Lawrence O Hall; Dmitry B Goldgof
Journal:  J Med Imaging (Bellingham)       Date:  2020-04-06

8.  Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.

Authors:  Pei N Ding; Tara L Roberts; Wei Chua; Therese M Becker; Nicole Caixeiro; Paul de Souza; Bo Gao; Chee K Lee; Malinda Itchins; Helen Westman; Stephen Clarke; Prunella Blinman; Steven Kao; Tom John; Jose L Leal; Victoria J Bray
Journal:  Transl Lung Cancer Res       Date:  2021-04

9.  A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.

Authors:  Holger Moch; Alwin Krämer; Chantal Pauli; Tilmann Bochtler; Linda Mileshkin; Giulia Baciarello; Ferran Losa; Jeffrey S Ross; George Pentheroudakis; George Zarkavelis; Suayib Yalcin; Mustafa Özgüroğlu; Andreas Beringer; Jeremy Scarato; Mathis Mueller-Ohldach; Marlene Thomas
Journal:  Oncologist       Date:  2021-03-25

10.  Determination of prognostic factors of surgically treated pathological Stage IIIA non-small cell lung cancer.

Authors:  Muhammet Sayan; Elgun Valiyev; Merve Satır Türk; Aynur Baş; Ali Çelik; İsmail Cüneyt Kurul; Olgun Kadir Arıbaş; Abdullah İrfan Taştepe
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-07-28       Impact factor: 0.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.